Hemorrhagic Shock Treatment Market, By Drug Type, By Distribution channel and By Region

PUBLISHED: March 25, 2025

PAGES: 280 Pages

DELIVERY TIME: 2-3 business days

ADD TO COMPARE

SELECT AN OPTION

Description

Hemorrhagic Shock Treatment Market is estimated to be valued at USD 224.6 Mn in 2025 and is expected to reach USD 303.6 Mn by 2032, growing at a compound annual growth rate (CAGR) of 4.4% from 2025 to 2032.

Report Coverage		Report Details
Base Year:	2024	Market Size in 2025:	USD 224.6 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	4.40%	2032 Value Projection:	USD 303.6 Mn

Hemorrhagic shock is a condition resulting in tissue perfusion and inadequate delivery of oxygen and nutrients to cells. A traumatic injury can cause hemorrhagic shock if the bleeding does not stop immediately. The primary treatment for hemorrhagic shock is immediate control of the source of bleeding and fluid replacement. In CHS (controlled hemorrhagic shock), fluid replacement is prescribed to normalize hemodynamic parameters when the source of bleeding is stopped. Hemorrhagic shock is a rare condition that occurs in many gynecological or obstetric situations. In this condition, decreased blood volume results in sympathetic compensation with tachycardia, peripheral vasoconstriction, and increased myocardial contractility. This can increase the oxygen demand of the heart muscle.

Market Dynamics

With a broader understanding of the pathophysiology of hemorrhagic shock, treatment in trauma has expanded from a simple massive transfusion method to a more comprehensive management strategy of damage control resuscitation. For instance, September 1, 2022, VirTech developed a hemoglobin-based solution with blood-like oxygen carrying capacity that caught the attention of the Pentagon, the US Department of Defense. This division of the US government made a contribution of US$ 13 million that is driving toward the clinical research phase of the project. The objective is to use the product to prevent hemorrhagic shock in trauma patients and to give better survival to organs donated for transplantation.The Pentagon was interested in the possibility of the solution preventing hemorrhagic shock, a problem that affects military personnel in combat or civilians who suffer trauma, such as automobile accidents. In these cases, hemorrhagic shock is usually the main cause of death, as there is often no time for a transfusion. Research carried out so far shows that the solution, injected into the body as a temporary blood substitute, considerably increases the time available for the victim to arrive at a hospital for transfusion.

Key features of the study:

This report provides an in-depth analysis of the global hemorrhagic shock treatment market and provides market size (US$ Mn) and compound annual growth rate (CAGR) for the forecast period 2025-2032, considering 2024 as the base year.
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global hemorrhagic shock treatment market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Biomedica Management Corporation, NuvOxPharma LLC, Leading BioSciences, Inc, F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Boehringer Ingelheim International GmbH, Johnson & Johnson Services Inc, AstraZeneca, Daiichi Sankyo Company, Limited, Teva Pharmaceutical Industries Ltd., Novartis AG, ZydusCadila, Amneal Pharmaceuticals LLC.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global hemorrhagic shock treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hemorrhagic shock treatment market.

Detailed Segmentation:

Global Hemorrhagic Shock Treatment Market, By Drug Type:
- NVX-408
- YW-356
- LB-1148
- Neutrolide
- Others
Global Hemorrhagic Shock Treatment Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Channels
Global Hemorrhagic Shock Treatment Market, By Region:
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
Company Profiles
- Biomedica Management Corporation
- NuvOxPharma LLC
- Leading BioSciences, Inc
- F. Hoffmann-La Roche Ltd
- Bristol-Myers Squibb Company
- Boehringer Ingelheim International GmbH
- Johnson & Johnson Services Inc
- AstraZeneca
- Daiichi Sankyo Company, Limited
- Teva Pharmaceutical Industries Ltd.
- Novartis AG
- ZydusCadila
- Amneal Pharmaceuticals LLC

Product Code: CMI4097

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug Type
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Recent Product Launches
Epidemiology
Merger, Acquisition, and Collaboration
Regulatory Scenario
Key Developments
PEST Analysis

4. Global Hemorrhagic Shock Treatment Market- COVID-19 Impact Analysis

Economic Impact
COVID-19 Epidemiology
Impact on Supply and Demand

5. Global Hemorrhagic Shock Treatment Market, By Drug Type, 2020-2032, (US$ Million)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
NVX-408
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
YW-356
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
LB-1148
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
Neutrolide
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)

6. Global Hemorrhagic Shock Treatment Market, By Distribution Channel, 2020-2032, (US$ Million)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
Online Channels
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)

7. Global Hemorrhagic Shock Treatment Market, By Region, 2020-2032, (US$ Million)

Introduction
- Market Share Analysis, By Region, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Region, 2021-2032
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Million)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Million)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Million)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Million)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Million)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2020-2032, (US$ Million)
  - North Africa
  - Central Africa
  - South Africa

8. Competitive Landscape

Biomedica Management Corporation
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
NuvOxPharma LLC
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Leading BioSciences, Inc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Hoffmann-La Roche Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Bristol-Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Boehringer Ingelheim International GmbH
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Johnson & Johnson Services Inc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
AstraZeneca
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Daiichi Sankyo Company, Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
ZydusCadila
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Amneal Pharmaceuticals LLC
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies